|Bid||114.3600 x 100|
|Ask||114.4500 x 100|
|Day's Range||96.3400 - 116.9315|
|52 Week Range||31.3800 - 116.9315|
|PE Ratio (TTM)||-22.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
One biotech's phase 3 success means competition for the other.
Alnylam gapped up Wednesday — to Ionis' detriment — after reporting positive results in a late-stage trial of a drug to treat a rare disease.
Get ready for a flurry of activity from this biotech pioneer.